Stock Events

Qilian International Group ltd 

$5.41
10
-$0.35-6.08% Friday 20:00

Statistics

Day High
5.41
Day Low
5.41
52W High
6.69
52W Low
1.78
Volume
330
Avg. Volume
25,380
Mkt Cap
38.68M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

29AprExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q2 2022
Q2 2023
Q1 2024
0
0.02
0.05
0.07
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QLI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Zai Lab Limited
ZLAB
Mkt Cap1.99B
Zai Lab Limited operates in the biopharmaceutical sector in China, focusing on developing innovative medicines, directly competing with Qilian's pharmaceutical products.
BeiGene
BGNE
Mkt Cap21.34B
BeiGene, Ltd. is a biotechnology company that develops molecularly targeted and immuno-oncology drugs for cancer treatment, competing in the pharmaceuticals market in China.
HUTCHMED (China) Limited
HCM
Mkt Cap3.04B
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in oncology and autoimmune diseases, similar to Qilian's focus areas.
FibroGen
FGEN
Mkt Cap36.71M
FibroGen, Inc. discovers, develops, and commercializes therapeutics to treat serious unmet medical needs, competing in the same therapeutic areas as Qilian.
Can-Fite Biopharma
CANF
Mkt Cap12.37M
Can-Fite BioPharma Ltd. is a biotechnology company developing drugs for cancer, liver, and inflammatory diseases, areas that overlap with Qilian's product development.
Karyopharm Therapeutics
KPTI
Mkt Cap94.78M
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company that focuses on the discovery and development of novel drugs for the treatment of cancer and other major diseases, competing in the oncology segment with Qilian.
Aptose Biosciences
APTO
Mkt Cap7.35M
Aptose Biosciences Inc. is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology, directly competing with Qilian's research and development focus.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including competition in the therapeutic areas targeted by Qilian.
Merck
MRK
Mkt Cap300.25B
Merck & Co., Inc. is a global healthcare company that offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing across several of Qilian's business areas.

About

Health Technology
Pharmaceuticals: Major
Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.
Show more...
CEO
Employees
298
Country
KY
ISIN
KYG7307E1070

Listings